Not_yet_recruitingNANCT07521488

Application of Large Language Model-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Patients After Cardiac Surgery: A Prospective Randomized Controlled Study

Sponsor: Beijing Anzhen Hospital

Trial Details

ConditionCoronary Artery Bypass Grafting, Heart Valve Disease, Aortic Aneurysm, Aortic Dissection, Congenital Heart Disease, Cardiac Surgical Procedures
InterventionLLM-Based Intelligent Health Management Assistant
PhaseNA
StatusNot_yet_recruiting
Participants500
Est. Completion31 Dec 2027
Last Updated13 Apr 2026

Primary Outcome

Composite Major Adverse Cardiac and Cerebrovascular Events (MACCE)

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: 1. Aged 18 years or older, any sex 2. Underwent cardiac surgery at the Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, including but not limited to: coronary artery bypass grafting (CABG), heart valve replacement or repair (aortic valve, mitral valve, or tricuspid valve surgery), great vessel surgery (aortic dissection or aortic aneurysm repair), congenital heart disease correction, or cardiac assist device implantation 3. Clinically stable after surgery and eligible for hospital discharge 4. Has access to a smartphone and is capable of independently operating a mobile application, or has a family member available to assist with operation 5. Voluntarily participates in the study, understands and signs the informed consent form, and is able to comply with the study protocol requirements Exclusion Criteria: 1. Postoperative intensive care unit (ICU) stay exceeding 30 days, or presence of severe uncontrolled postoperative complications such as persistent infection or multi-organ failure 2. Life expectancy less than 12 months due to advanced malignancy or end-stage organ failure 3. Severe cognitive impairment, psychiatric disorder, or inability to understand and use a mobile application without available caregiver assistance 4. Heart transplant recipient 5. Currently participating in another interventional clinical study 6. Anticipated inability to complete 12-month follow-up

Trial Sites

Countries

China
View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service